预测性数字双胞胎在瘤学中对患者特定决策的量化不确定性
Graham Pash1, Umberto Villa1, David A Hormuth1,2
1Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX, 78712, USA.
ArXiv
|June 4, 2025
概括
这项研究引入了个性化医疗的数字双胞胎方法,将成像数据与机械模型集成,以预测瘤进展和量化不确定性,以获得更好的患者结果.
科学领域:
- 生物医学工程 生物医学工程
- 计算生物学 计算生物学
- 医疗成像医学成像
背景情况:
- 个性化医疗需要准确的预测模型,以量化不确定性为信任和基于风险的决策.
- 数字双胞胎提供个性化的建模潜力,超出了人口层面的风险缓解,旨在改善个体患者的治疗结果.
- 整合患者数据与机械模型对于创建有效的生物医学数字双胞胎至关重要.
研究的目的:
- 利用纵向成像数据和机械模型开发一个端到端的方法来估计和预测时空瘤进展.
- 从稀疏和杂的患者测量得出的预测中量化不确定性.
- 在决策过程中展示该方法的应用,包括对成像频率的最佳实验设计.
主要方法:
- 使用统计反向问题方法将非侵入性成像数据与瘤进展的反应扩散模型集成.
- 该方法结合了患者特定的解剖学,并估计了空间变化的模型参数.
- 为了确定不确定性量化,使用了前模型的有效并行实现和可扩展的贝叶斯后近似.
主要成果:
- 该方法在虚拟患者上使用合成数据成功验证,控制模型不足,噪音和数据收集频率.
- 该研究表明,成像频率对预测准确性和决策的影响.
- 模型验证是在公开可用的纵向成像数据的患者队列上进行的,显示了临床相关性.
结论:
- 开发的数据决策方法允许使用成像数据和机械模型进行个性化瘤进展建模.
- 这种方法提供了一种可处理但又严格的不确定性量化方法,这对于临床信任和决策支持至关重要.
- 这些发现突显了数字双胞胎在通过准确,针对患者的预测来推进个性化医学的潜力.
更多相关视频
04:49Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021
6.5K
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
964
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
